长春高新1700亿元市值蒸发，集采、人口、竞品冲击如何击溃生长激素神话｜创新药观察 本报（chinatimes.net.cn）记者张斯文 于娜 北京报道 华夏时报 五年前，长春高新还是投资者口中"永不落幕的成长神话"，"东北药茅"的金字招牌熠熠生辉。 然而，泡沫终有破碎时。当繁华落尽，徒留的是一地狼藉的鸡毛。公司股价从2021年那令人眩目的 485.82元历史高点，断崖式跌入百元关口，市值也在惊涛骇浪中从2100亿元的云端滑落至375亿元的谷 底，蒸发近1700亿元。昔日的千亿巨头，如今在资本市场已然门前冷落鞍马稀。 长春高新股价的轰然坍塌像一面镜子，冰冷地映射出中国医药产业在告别"神药依赖"旧时代，向全面创 新艰难转身过程中，那难以回避的深刻阵痛。 （来源：WIND） 2025年4月20日，长春高新发布了近20年来首份营收下滑的年报：2024年营收134.66亿元，同比下降 7.55%；净利润27.08亿元，同比大幅下降43.01%。 （来源：WIND） 更令投资者心惊的是，公司2025年一季度的业绩依旧延续颓势，当季净利润4.69亿元，同比再降 47.36%。 业绩从增长到"腰斩" 长春高新过往的业绩可以 ...

Core Insights - Guangdong Province has approved a list of 107 innovative drug and medical device products, including 46 innovative drugs, to enhance the application of these products in public medical institutions [1][5] - Among the approved innovative drugs, 10 are anti-cancer drugs, representing 22% of the total, showcasing Guangdong's strength in cancer treatment research and manufacturing [3][5] Summary by Category Innovative Drug List - The list includes 107 innovative products, with 46 classified as innovative drugs [1] - The anti-cancer drugs cover various prevalent malignant tumors, indicating significant research capabilities in this area [3] Anti-Cancer Drugs - The 10 anti-cancer drugs listed include: - Aorebatinib for chronic myeloid leukemia - Sapalizumab for cervical cancer and Hodgkin lymphoma - Socazolimab for cervical cancer - Sidabenzamide for diffuse large B-cell lymphoma - Cardunilimab for cervical cancer and gastric adenocarcinoma - Acetate injection for prostate cancer - Trelizumab for multiple cancers including Hodgkin lymphoma and non-small cell lung cancer - Panitumumab for multiple cancers including non-small cell lung cancer - Obinutuzumab for adult lymphomas - Ivorilumab for lung cancer [4] Industry Development - Guangdong pharmaceutical companies are accelerating their internationalization, exemplified by the approval of Panitumumab for the U.S. market [5] - The integration of industry, academia, and research has been pivotal in the development of these innovative drugs, with local scholars leading significant research efforts [5] - The comprehensive innovation capability from research to clinical application is being established, enhancing Guangdong's competitive edge in the global biopharmaceutical industry [5]